Edition:
United States

Mylan NV (MYL.O)

MYL.O on Nasdaq

30.98USD
19 Sep 2017
Change (% chg)

$-0.52 (-1.65%)
Prev Close
$31.50
Open
$31.52
Day's High
$31.69
Day's Low
$30.72
Volume
7,100,082
Avg. Vol
6,177,640
52-wk High
$45.87
52-wk Low
$29.39

Chart for

About

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The... (more)

Overall

Beta: 1.30
Market Cap(Mil.): $16,892.84
Shares Outstanding(Mil.): 536.28
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.87 16.18
EPS (TTM): -- -- --
ROI: -- 15.15 14.60
ROE: -- 16.38 13.87

Fitch Affirms Jubilant Pharma at 'BB-'; Outlook Stable

(The following statement was released by the rating agency) SINGAPORE/MUMBAI, September 19 (Fitch) Fitch Ratings has affirmed Singapore-based Jubilant Pharma Limited's (JPL) Long-Term Foreign-Currency Issuer Default Rating (IDR) at 'BB-'. The Outlook is Stable. The agency has also affirmed JPL's senior unsecured rating and the rating on its USD300 million 4.875% senior unsecured notes due 2021 at 'BB'. JPL's ratings reflect moderate linkages with parent, Jubilant Life Sciences Limited (JLS), whi

4:19am EDT

Biosimilar cancer drug threat closing in for Roche

LONDON The long-heralded threat of cut-price competition to its top-selling biological cancer medicines is finally becoming a reality for Roche, the world's biggest maker of oncology treatments.

Sep 18 2017

Biosimilar cancer drug threat closing in for Roche

LONDON, Sept 18 The long-heralded threat of cut-price competition to its top-selling biological cancer medicines is finally becoming a reality for Roche, the world's biggest maker of oncology treatments.

Sep 18 2017

Samsung Bioepis wins EU endorsement for first Herceptin copy

* Bioepis could receive 4 EU biosimilar approvals in two years

Sep 15 2017

BRIEF-Mylan expands women's healthcare portfolio with launch of generic Minastrin 24 FE tablets

* Mylan expands women's healthcare portfolio with launch of generic Minastrin 24 FE tablets

Sep 14 2017

BRIEF-Mylan names Dennis Zeleny as chief human relations officer

* Mylan names Dennis Zeleny as chief human relations officer Source text for Eikon: Further company coverage:

Sep 13 2017

BRIEF-Otsuka and Mylan announce license agreement to commercialize Delamanid

* Mylan NV- Otsuka Pharmaceutical Co Ltd, co entered into license agreement between their respective subsidiaries ONPG and Mylan Pharmaceuticals Private Limited

Aug 24 2017

Mylan, U.S. finalize $465 million EpiPen settlement

BOSTON Mylan NV has finalized a $465 million settlement resolving U.S. Justice Department claims it overcharged the government for its EpiPen emergency allergy treatment, which became the center of a firestorm over price increases.

Aug 17 2017

UPDATE 5-Mylan, U.S. finalize $465 million EpiPen settlement

BOSTON, Aug 17 Mylan NV has finalized a $465 million settlement resolving U.S. Justice Department claims it overcharged the government for its EpiPen emergency allergy treatment, which became the center of a firestorm over price increases.

Aug 17 2017

BRIEF-Mylan finalizes settlement on Medicaid rebate classification for Epipen

* Mylan finalizes settlement agreement on Medicaid rebate classification for Epipen auto-injector

Aug 17 2017

Earnings vs. Estimates